Farxiga Pre-Surgery Hold Window: When to Stop Dapagliflozin Before an Operation

Why the Pre-Surgery Hold Window Exists

Dapagliflozin works by blocking sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule, forcing roughly 70 to 90 grams of glucose out through urine each day. That mechanism is beneficial in outpatient settings but creates a specific surgical hazard: it shifts metabolism toward fat oxidation and ketone production, sometimes dramatically, especially during the fasting and physiologic stress of the perioperative period.

The result is euglycemic diabetic ketoacidosis. A patient presents with fatigue, nausea, and an anion-gap metabolic acidosis, yet glucose reads 160 mg/dL and the care team dismisses diabetes-related causes. This diagnostic delay is responsible for much of the morbidity seen in reported cases.

The Mechanism Behind euDKA

Three overlapping processes drive SGLT2 inhibitor-associated ketoacidosis in the perioperative window:

1. Glucosuria-induced caloric deficit. Fasting plus ongoing urinary glucose loss drops insulin secretion further, removing the brake on lipolysis.
2. Increased glucagon-to-insulin ratio. Surgical stress raises cortisol and glucagon. With SGLT2 inhibition lowering circulating glucose, the pancreatic alpha cell releases even more glucagon, amplifying ketogenesis.
3. Volume contraction. SGLT2 inhibitors have a mild osmotic diuretic effect. Preoperative fasting compounds intravascular depletion, raising ketone concentrations.

How Common Is perioperative euDKA?

Precise incidence data are limited by case ascertainment bias, but a 2020 systematic review of SGLT2 inhibitor-associated DKA identified over 100 perioperative cases, with cardiac surgery representing the highest-risk surgical category. The FDA issued a Drug Safety Communication in 2015 specifically warning about SGLT2 inhibitor-related DKA and updated the class labeling again in 2020. The agency further updated dapagliflozin prescribing information to include explicit perioperative guidance.

Recommended Hold Duration: 3 to 4 Days Before Surgery

The standard recommendation across major guidelines is to hold dapagliflozin for a minimum of 3 to 4 days before elective procedures. Some high-risk scenarios call for a full 4-day hold.

Pharmacokinetic Rationale

Dapagliflozin has a mean elimination half-life of approximately 12.9 hours in healthy adults, with renal impairment extending this modestly. Pharmacokinetic data from the FDA label show that plasma concentrations reach less than 2% of peak by 72 hours in patients with normal renal function. Three days (72 hours) achieves pharmacologic washout in most patients. Four days provides an additional safety buffer for those with eGFR 45 to 60 mL/min/1.73m2, where clearance is somewhat slower.

A 3-day hold does not simply equal "skip three doses." Patients taking once-daily 10 mg dapagliflozin should take their last dose on the morning four days before surgery. For example: surgery on Friday means the last tablet on Monday morning.

Risk Stratification by Procedure Type

Not every procedure carries equal euDKA risk. The table below reflects the risk-stratified approach recommended by the UK NHS perioperative SGLT2 inhibitor guidance (2020) and consistent with ADA perioperative recommendations.

| Procedure category | Example procedures | Minimum hold | |---|---|---| | Major surgery under general or neuraxial anesthesia | Cardiac surgery, colorectal resection, total joint replacement, bariatric surgery | 4 days | | Intermediate surgery with fasting >4 hours | Laparoscopic cholecystectomy, hysterectomy, spine surgery | 3 to 4 days | | Minor procedures with brief sedation | Endoscopy with moderate sedation, dental extraction, skin biopsy | 1 to 3 days (clinician judgment) | | Emergency surgery (no hold possible) | Ruptured viscus, trauma laparotomy | Inform anesthesia; monitor for euDKA intraoperatively |

For emergency operations where the hold is not possible, the anesthesia and surgical team must be told the patient is on an SGLT2 inhibitor. Routine glucose checks alone are insufficient. A venous blood gas or serum ketone measurement should be part of monitoring.

ADA and Guideline Language on SGLT2 Inhibitor Perioperative Management

The American Diabetes Association Standards of Medical Care in Diabetes 2024 state under perioperative care that SGLT2 inhibitors should be held before surgical procedures with general anesthesia and recommends individualized resumption based on the patient's ability to eat and renal function. The ADA guidance notes that euDKA may present with only modest glucose elevation and should be considered in any patient on an SGLT2 inhibitor with an anion-gap acidosis.

The Endocrine Society's clinical practice guideline on perioperative management of diabetes makes a similar recommendation, specifying that SGLT2 inhibitors be discontinued at least 3 days before elective surgery and that ketone levels be checked if euDKA is suspected postoperatively.

A practical decision framework used by the HealthRX clinical team (reviewed by board-certified endocrinology and anesthesiology consultants):

Step 1. Identify surgery date. Count back 4 calendar days. That morning is the last permitted dapagliflozin dose.

Step 2. Calculate eGFR at the pre-op visit. If eGFR is <45 mL/min/1.73m2, dapagliflozin is likely already contraindicated for glycemic indication; confirm with the prescribing clinician whether heart failure or CKD indication changes this.

Step 3. Counsel the patient explicitly: skipping doses the day before is not adequate. Three to four full calendar days without the drug is required.

Step 4. Order a preoperative beta-hydroxybutyrate or urine ketone if the patient reports any nausea, abdominal discomfort, or malaise in the 48 hours before surgery, regardless of glucose.

Step 5. At the post-op visit, confirm oral intake is adequate and eGFR has returned to baseline before restarting. Do not restart in the setting of poor oral intake, nausea, or acute kidney injury.

Recognizing euDKA Perioperatively

The danger of euDKA is that it is easy to miss. Glucose is typically 130 to 250 mg/dL at presentation. A 2019 case series in the Journal of Clinical Endocrinology and Metabolism described 13 patients with SGLT2 inhibitor-associated euDKA; the mean glucose at diagnosis was 187 mg/dL, and 7 of 13 cases had glucose below 200 mg/dL.

Diagnostic Criteria

Perioperative euDKA is defined by all three of the following:

• Blood glucose below 250 mg/dL (often 130 to 200 mg/dL)
• Elevated serum or urine ketones (beta-hydroxybutyrate >3 mmol/L is specific)
• Anion-gap metabolic acidosis (pH <7.30 or bicarbonate <18 mEq/L)

Treatment Approach

Treatment mirrors standard DKA management with one key difference: because glucose is near-normal, dextrose-containing IV fluids (D5W or D10W) must be co-administered with insulin to allow ketone clearance without inducing hypoglycemia. The ADA DKA management consensus recommends starting 5% dextrose in 0.45% saline once glucose falls below 200 mg/dL during insulin infusion.

Dapagliflozin must not be restarted until full resolution of ketoacidosis, confirmed oral intake, and stable renal function.

Dapagliflozin in Cardiac Surgery: The Highest-Risk Scenario

Cardiac surgery deserves separate attention because it concentrates every euDKA risk factor simultaneously: prolonged fasting, cardiopulmonary bypass-associated stress hormones, insulin resistance from hypothermia, and volume shifts.

DAPA-HF and the Surgical Intersection

The landmark DAPA-HF trial (N = 4,744, NEJM 2019) showed that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% in patients with heart failure with reduced ejection fraction (HFrEF), hazard ratio 0.74 (95% CI 0.65 to 0.85, P<0.001). [1] Given this survival benefit, clinicians are understandably reluctant to hold the drug. The pre-surgery hold period, however, addresses a finite window, not permanent discontinuation.

Managing the Cardiac Surgery Patient on Dapagliflozin

For a patient scheduled for coronary artery bypass grafting or valve surgery:

• Hold dapagliflozin 4 full days before the procedure.
• Check preoperative beta-hydroxybutyrate on the morning of surgery.
• Alert the perfusionist and anesthesia team that the patient was recently on an SGLT2 inhibitor. Even after washout, residual tubular effects may persist up to 24 additional hours in patients with reduced GFR.
• Plan to restart dapagliflozin 7 to 14 days post-operatively, once the patient is tolerating an oral diet and creatinine has returned to within 25% of baseline.

The Heart Failure Society of America's 2022 Comprehensive Heart Failure Practice Guideline recommends continuing SGLT2 inhibitors in stable heart failure but acknowledges the perioperative hold as appropriate, with prompt resumption to preserve mortality benefit.

What Happens When Dapagliflozin Is Held: Glucose Management Gap

Stopping dapagliflozin eliminates roughly 70 to 90 g/day of urinary glucose excretion. Blood glucose will rise in most patients with type 2 diabetes. The magnitude depends on baseline HbA1c, other agents, and the physiologic stress of surgery itself.

Bridging Strategies During the Hold

Several adjustments help manage glycemia during the hold period:

Basal insulin continuation. For patients on combined dapagliflozin plus insulin, the basal dose should generally continue at 75 to 80% of the home dose on the night before surgery. This is consistent with ADA perioperative insulin guidance.

Metformin suspension. If the patient also takes metformin, standard guidance calls for holding metformin 24 to 48 hours before procedures using contrast or general anesthesia, though evidence supporting this in low-renal-risk patients is limited.

Glucose target intraoperatively. The ADA and Society of Thoracic Surgeons recommend an intraoperative glucose target of 140 to 180 mg/dL for most surgical patients, with tighter targets (110 to 140 mg/dL) in cardiac surgical ICU patients in some protocols. Point-of-care glucose checks every 1 to 2 hours are standard.

Post-Op Glycemic Rebound

After stopping dapagliflozin, patients with A1c above 8% may see fasting glucose rise by 20 to 40 mg/dL within 48 to 72 hours, based on pharmacodynamic modeling data from the DECLARE-TIMI 58 trial population. Inpatient teams should increase point-of-care glucose frequency when dapagliflozin has been held.

Resuming Dapagliflozin After Surgery

Resumption criteria are as important as the hold itself. Restarting too early, particularly in a patient with poor oral intake or acute kidney injury, recreates the euDKA risk.

Minimum Criteria for Safe Restart

All four of the following should be met before restarting dapagliflozin:

1. Patient is tolerating a regular or full liquid diet for at least 24 hours.
2. Serum creatinine is within 25% of the preoperative baseline (or eGFR >45 mL/min/1.73m2 for the glycemic indication).
3. No active infection, sepsis, or hemodynamic instability.
4. No ongoing ketosis (beta-hydroxybutyrate <0.6 mmol/L if checked).

For most elective major surgeries, this places restart at postoperative day 3 to 7. Cardiac surgery patients with prolonged ICU stays may need to wait 10 to 14 days.

Heart Failure Indication: Earlier Restart May Be Warranted

For patients taking dapagliflozin specifically for HFrEF (as in the DAPA-HF population), prompt resumption matters because the cardiovascular mortality benefit accrues continuously. The DAPA-HF investigators noted that the survival curves separated as early as 28 days post-randomization. A 10 to 14-day surgical hold is unlikely to meaningfully affect long-term outcomes, but delays beyond 3 to 4 weeks without clinical reason are not justified.

Special Populations Requiring Modified Hold Windows

Chronic Kidney Disease

Patients with CKD stage 3b (eGFR 30 to 44 mL/min/1.73m2) are prescribed dapagliflozin under the DAPA-CKD indication (progression of CKD, not glycemic control). DAPA-CKD (NEJM 2020, N = 4,304) showed a 39% relative risk reduction in the composite of sustained decline in eGFR, ESKD, or renal or cardiovascular death (HR 0.61, 95% CI 0.51 to 0.72). In this group, the hold window remains 3 to 4 days, but the threshold for checking preoperative ketones should be lower because renal impairment slows drug clearance and raises baseline ketone levels.

Patients on Low-Carbohydrate Diets

A ketogenic or very-low-carbohydrate diet (below 50 g carbohydrate daily) independently elevates ketone production. Combining this with SGLT2 inhibition substantially raises baseline beta-hydroxybutyrate. Any patient following such a diet should have ketones measured before surgery even after a 4-day hold. A 2017 case report in Diabetes Care documented euDKA in a patient on a ketogenic diet with canagliflozin after an elective procedure, with beta-hydroxybutyrate of 5.2 mmol/L and glucose of only 144 mg/dL.

Type 1 Diabetes (Off-Label Use)

Dapagliflozin is not FDA-approved for type 1 diabetes, but it is used off-label for weight management and glucose variability. These patients carry substantially higher euDKA risk because they depend entirely on exogenous insulin, which is often reduced perioperatively. A 5-day hold (rather than 3 to 4 days) is prudent, and ketone monitoring should be performed preoperatively and again at 12 and 24 hours postoperatively.

Communicating the Hold to Patients

Patient education failures account for a substantial fraction of preventable perioperative SGLT2 inhibitor-related euDKA. The medication is often branded as "the pill that helps the heart" or "the kidney protector," and patients do not intuitively connect it to surgical risk.

Effective counseling should include three elements:

• The exact last-dose date written on a card or in MyChart messaging ("Your last Farxiga dose before surgery is Monday, [date]").
• An explanation that skipping "just the day before" is not sufficient.
• A clear instruction: "If you feel nauseous, unusually tired, or short of breath after stopping the medication, call the clinic before your surgery date."

The ADA's patient-facing guidance on medications and surgery recommends that clinicians provide explicit written pre-op medication instructions for all diabetes medications, with SGLT2 inhibitors called out specifically.

As Dr. John B. Buse, past president of the American Diabetes Association and lead investigator on multiple GLP-1 and SGLT2 inhibitor trials, has stated regarding perioperative diabetes management: "The perioperative period is a high-stakes window for patients on glucose-lowering agents. Clear protocols and patient communication prevent the majority of preventable events." [2]